30 December 2019 - - Golan Bitton, CEO of Univo Pharmaceuticals (TASE: UNVO), was elected as a board member to Israel-based biotechnology company Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI)
at its recent annual general meeting, the company said.

In September 2019, Can-Fite BioPharma and Univo Pharmaceutical, a medical cannabis company, entered into a collaboration agreement to co-develop cannabis derived pharmaceutical products based on the platform technology of Can-Fite in the fields of cancer, inflammatory, autoimmune, and metabolic diseases.

Golan Bitton has many years of managerial experience in the Israeli Ministry of Defense. During his tenure there, he Implemented and managed multi-m dollar projects for the Israeli government.

Golan holds a B.A. in Economics and Business Management from Max Stern Academic College and Computer Engineering from Negev University. Golan is the founder of Univo Pharmaceuticals and is considered TODAY as one of the leading worldwide experts in the cannabis arena.

Can-Fite is uniquely positioned to contribute its deep pharmaceutical development expertise to the medical cannabis market, based on findings published in peer reviewed scientific journals, that demonstrate CBDs also bind to the A3 adenosine receptor, which is over-expressed in pathological cells.

A3AR is a target that Can-Fite believes can be used as a predictor and selector for the use of each type of CBD and more cannabinoids in the treatment of specific diseases. Can-Fite is a leader in the research and development of drugs that target A3AR.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.

The company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis.

Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma, the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis.

Namodenoson has been granted Orphan Drug Designation in the US and Europe and Fast Track Designation as a second line treatment for HCC by the US Food and Drug Administration.

Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.

CF602, the company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction.